

SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina

26, 495-511

DOI: [10.1097/01.iae.0000225766.75009.3a](https://doi.org/10.1097/01.iae.0000225766.75009.3a)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration Twelve-Week Results of an Uncontrolled Open-Label Clinical Study. <i>Ophthalmology</i> , 2005, 112, 1035-1047.e9.	2.5	626
2	A review of drug options in age-related macular degeneration therapy and potential new agents. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2355-2368.	0.9	8
3	Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2006, 113, 2002-2011.e2.	2.5	187
4	Advances in Imaging of the Optic Disc and Retinal Nerve Fiber Layer. <i>Journal of Neuro-Ophthalmology</i> , 2006, 26, 284-295.	0.4	31
5	Expanding Treatment Options in Age-related Macular Degeneration. <i>International Ophthalmology Clinics</i> , 2006, 46, 123-129.	0.3	9
7	Photodynamic therapy in macular diseases. <i>Expert Review of Ophthalmology</i> , 2006, 1, 97-112.	0.3	1
8	A Very Effective Treatment for Neovascular Macular Degeneration. <i>New England Journal of Medicine</i> , 2006, 355, 1493-1495.	13.9	66
9	The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. <i>British Journal of Ophthalmology</i> , 2006, 90, 1344-1349.	2.1	502
10	Is intravitreal bevacizumab (Avastin) safe?. <i>British Journal of Ophthalmology</i> , 2006, 90, 1333-1334.	2.1	25
11	Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. <i>British Journal of Ophthalmology</i> , 2007, 91, 1716-1717.	2.1	23
12	Effect of anti-VEGF antibody on retinal ganglion cells in rats. <i>British Journal of Ophthalmology</i> , 2007, 91, 1230-1233.	2.1	62
13	Bevacizumab for ophthalmic diseases. <i>Expert Review of Ophthalmology</i> , 2007, 2, 369-378.	0.3	4
14	Therapeutic effects of ranibizumab in neovascular age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2007, 2, 679-693.	0.3	1
15	Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). <i>British Journal of Ophthalmology</i> , 2007, 91, 602-604.	2.1	48
16	Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Angioid Streaks. <i>JAMA Ophthalmology</i> , 2007, 125, 1422.	2.6	43
17	Computed tomography screening for lung cancer. <i>BMJ: British Medical Journal</i> , 2007, 334, 271-271.	2.4	15
18	Improving the mental health of offenders in primary care. <i>BMJ: British Medical Journal</i> , 2007, 334, 267-268.	2.4	4
19	Reducing harm from radiotherapy. <i>BMJ: British Medical Journal</i> , 2007, 334, 272-272.	2.4	14

#	ARTICLE	IF	CITATIONS
20	Current Treatment of Age-Related Macular Degeneration. <i>Optometry and Vision Science</i> , 2007, 84, E559-E572.	0.6	29
21	Inhibiting Angiogenesis in Retinoblastoma. <i>Ophthalmic Research</i> , 2007, 39, 188-190.	1.0	16
22	CLINICAL AND FUNDAMENTAL ASPECTS OF ANGIOGENESIS AND ANTI-ANGIOGENESIS. <i>Acta Clinica Belgica</i> , 2007, 62, 162-169.	0.5	16
23	Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Exudative Age-Related Macular Degeneration and Diffuse Diabetic Macular Edema. <i>Ophthalmic Research</i> , 2007, 39, 139-142.	1.0	47
24	New treatments for neovascular acute macular degeneration. <i>BMJ: British Medical Journal</i> , 2007, 334, 269-270.	2.4	5
25	Complement, Innate Immunity and Ocular Disease. , 2007, 92, 105-114.		23
26	Anti-VEGF agents in the treatment of neovascular AMD. <i>Expert Review of Ophthalmology</i> , 2007, 2, 459-465.	0.3	1
27	Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. <i>British Journal of Ophthalmology</i> , 2007, 91, 827-831.	2.1	48
28	Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. <i>British Journal of Ophthalmology</i> , 2007, 91, 1318-1322.	2.1	149
29	The Therapeutic Effects of Intravitreal Bevacizumab in a Patient with Recalcitrant Idiopathic Polypoidal Choroidal Vasculopathy. <i>Seminars in Ophthalmology</i> , 2007, 22, 127-131.	0.8	28
30	Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2007, 125, 1357.	2.6	76
31	Preclinical Safety Evaluation of Intravitreal Injection of Full-Length Humanized Vascular Endothelial Growth Factor Antibody in Rabbit Eyes. <i>Investigative Ophthalmology and Visual Science</i> , 2007, 48, 1773-1781.	3.3	117
32	Preparing for the next flu pandemic. <i>BMJ: British Medical Journal</i> , 2007, 334, 268-269.	2.4	5
33	Vascular Endothelial Growth Factor in Aqueous Humor Before and After Intravitreal Injection of Bevacizumab in Eyes With Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2007, 125, 1363.	2.6	80
34	STANDARDIZED VISUAL ACUITY RESULTS ASSOCIATED WITH PRIMARY VERSUS SECONDARY BEVACIZUMAB (AVASTIN) TREATMENT FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 701-706.	1.0	39
35	PREDICTED BIOLOGIC ACTIVITY OF INTRAVITREAL BEVACIZUMAB. <i>Retina</i> , 2007, 27, 1196-1200.	1.0	64
36	RETINAL PIGMENT EPITHELIAL TEARS AFTER INTRAVITREAL BEVACIZUMAB INJECTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 541-551.	1.0	160
37	TREATMENT OF NAÏVE LESIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB. <i>Retina</i> , 2007, 27, 851-856.	1.0	23

#	ARTICLE	IF	CITATIONS
38	Neovascular AMD: Out of the Forest and Into the Trees. <i>Retina</i> , 2007, 27, 655-661.	1.0	2
39	TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 133-140.	1.0	194
40	INTRAVITREAL BEVACIZUMAB (AVASTIN) IN CENTRAL RETINAL VEIN OCCLUSION. <i>Retina</i> , 2007, 27, 1013-1019.	1.0	64
41	INTRAVITREAL BEVACIZUMAB COMBINED WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF OCCULT CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH SEROUS PIGMENT EPITHELIUM DETACHMENT IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 891-896.	1.0	36
42	INTRAVITREAL BEVACIZUMAB INJECTIONS FOR TREATMENT OF CENTRAL RETINAL VEIN OCCLUSION. <i>Retina</i> , 2007, 27, 1004-1012.	1.0	113
43	RANIBIZUMAB FOR TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 846-850.	1.0	28
44	Avastin Versus Lucentis: Ethical Issues in Treatment of Age-Related Macular Degeneration. <i>Retina</i> , 2007, 27, 1163-1165.	1.0	15
45	Antiangiogenic Therapy in Neovascular Age-related Macular Degeneration. <i>International Ophthalmology Clinics</i> , 2007, 47, 117-137.	0.3	12
46	INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 439-444.	1.0	154
48	Intravitreal Bevacizumab (Avastin) for the Treatment of Chorioretinal Vascular Diseases. <i>Techniques in Ophthalmology</i> , 2007, 5, 40-45.	0.1	0
49	RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 535-540.	1.0	62
50	Relative Cost of a Line of Vision in Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2007, 114, 847-854.	2.5	40
51	Interventions for Branch Retinal Vein Occlusion. <i>Ophthalmology</i> , 2007, 114, 835-854.	2.5	131
52	Pharmacokinetics of Intravitreal Bevacizumab (Avastin). <i>Ophthalmology</i> , 2007, 114, 855-859.	2.5	636
53	Verteporfin Therapy and Intravitreal Bevacizumab Combined and Alone in Choroidal Neovascularization due to Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2007, 114, 1179-1185.	2.5	134
54	Intravitreal Bevacizumab (Avastin) for Myopic Choroidal Neovascularization. <i>Ophthalmology</i> , 2007, 114, 2190-2196.e2.	2.5	127
55	Association of Complement Factor H and LOC387715 Genotypes with Response of Exudative Age-Related Macular Degeneration to Intravitreal Bevacizumab. <i>Ophthalmology</i> , 2007, 114, 2168-2173.	2.5	195
56	Pharmacokinetics of Intravitreal Ranibizumab (Lucentis). <i>Ophthalmology</i> , 2007, 114, 2179-2182.	2.5	497

#	ARTICLE	IF	CITATIONS
57	Intravitreal Bevacizumab (Avastin) for Neovascular Age-related Macular Degeneration: A Short-term Study. <i>American Journal of Ophthalmology</i> , 2007, 143, 510-512.	1.7	86
58	Intravitreal Bevacizumab for Idiopathic Choroidal Neovascularization After Previous Injection With Posterior Subtenon Triamcinolone. <i>American Journal of Ophthalmology</i> , 2007, 143, 507-509.e1.	1.7	38
59	Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy, Secondary to Punctate Inner Choroidopathy, or of Idiopathic Origin. <i>American Journal of Ophthalmology</i> , 2007, 143, 977-983.e1.	1.7	159
60	Optical Coherence Tomography Reader Agreement in Neovascular Age-related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2007, 144, 37-44.e1.	1.7	35
61	Treatment of Exudative Age-related Macular Degeneration: Many Factors to Consider. <i>American Journal of Ophthalmology</i> , 2007, 144, 281-283.	1.7	14
62	Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday Patients. <i>American Journal of Ophthalmology</i> , 2007, 144, 627-637.e2.	1.7	210
63	Intravitreal Bevacizumab Therapy for Neovascular Age-related Macular Degeneration with Large Submacular Hemorrhage. <i>American Journal of Ophthalmology</i> , 2007, 144, 886-892.e2.	1.7	91
64	Roles for VEGF in the adult. <i>Microvascular Research</i> , 2007, 74, 100-113.	1.1	164
65	Retinal and choroidal microangiopathies: Therapeutic opportunities. <i>Microvascular Research</i> , 2007, 74, 131-144.	1.1	60
66	Experimental hypoxia in human eyes: Implications for ischaemic disease. <i>Clinical Neurophysiology</i> , 2007, 118, 887-895.	0.7	24
67	Targeting Vascular Endothelial Growth Factor. <i>Drugs and Aging</i> , 2007, 24, 643-662.	1.3	43
68	Bevacizumab for Neovascular Ocular Diseases. <i>Annals of Pharmacotherapy</i> , 2007, 41, 614-625.	0.9	156
69	Local Tolerance and Systemic Safety of Pegaptanib Sodium in the Dog and Rabbit. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2007, 23, 452-466.	0.6	37
70	Emerging Therapies for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. <i>BioDrugs</i> , 2007, 21, 245-257.	2.2	63
71	Pegaptanib sodium for the treatment of ocular vascular disease. <i>Expert Review of Ophthalmology</i> , 2007, 2, 45-60.	0.3	1
72	Intravitreal Ranibizumab and Bevacizumab: A Review of Risk. <i>Seminars in Ophthalmology</i> , 2007, 22, 201-204.	0.8	60
73	Short-term intraocular pressure changes after intravitreal injection of bevacizumab. <i>Canadian Journal of Ophthalmology</i> , 2007, 42, 807-811.	0.4	164
75	Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. <i>British Journal of Ophthalmology</i> , 2007, 91, 128-130.	2.1	17

#	ARTICLE	IF	CITATIONS
76	Intravitreal Bevacizumab Therapy for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: 6-Month Results of an Open-Label Uncontrolled Clinical Study. <i>European Journal of Ophthalmology</i> , 2007, 17, 230-237.	0.7	32
78	Clinical applications and new developments of optical coherence tomography: an evidence-based review. <i>Australasian journal of optometry, The</i> , 2007, 90, 317-335.	0.6	73
79	Intravitreal VEGF-inhibitors: is Avastin® a generic substitute for Lucentis®?. <i>Acta Ophthalmologica</i> , 2007, 85, 2-4.	0.4	17
80	Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. <i>Acta Ophthalmologica</i> , 2007, 85, 563-565.	0.4	12
81	Treatment of choroidal neovascularization using intravitreal bevacizumab. <i>Acta Ophthalmologica</i> , 2007, 85, 526-533.	0.4	20
82	Large subretinal hemorrhage after intravitreal bevacizumab (Avastin®) for age-related macular degeneration. <i>Annals of Ophthalmology</i> , 2007, 39, 51-52.	0.0	11
88	Intravitreal anti-VEGF therapy in neovascular age-related macular degeneration: Bevacizumab versus Ranibizumab. <i>Spektrum Der Augenheilkunde</i> , 2008, 22, 370-375.	0.2	1
89	Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. <i>Japanese Journal of Ophthalmology</i> , 2008, 52, 52-56.	0.9	21
90	Activity of neovascular lesions treated with bevacizumab: comparison between optical coherence tomography and fluorescein angiography. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2008, 246, 811-815.	1.0	20
91	Antiangiogenic therapy and surgical practice. <i>British Journal of Surgery</i> , 2008, 95, 281-293.	0.1	9
92	Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib [®] treatment. <i>Acta Ophthalmologica</i> , 2008, 86, 456-458.	0.6	33
93	Complications in patients after intravitreal injection of bevacizumab. <i>Acta Ophthalmologica</i> , 2008, 86, 372-376.	0.6	179
94	A prospective study on intravitreal bevacizumab (Avastin [®]) for neovascular age-related macular degeneration of different durations. <i>Acta Ophthalmologica</i> , 2008, 86, 482-489.	0.6	86
95	The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. <i>Eye</i> , 2008, 22, 761-767.	1.1	40
96	Progress in understanding and treating age-related macular degeneration. <i>Eye</i> , 2008, 22, 739-741.	1.1	4
97	Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. <i>Australasian journal of optometry, The</i> , 2008, 91, 427-437.	0.6	60
98	Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 449-454.	1.3	31
99	Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 748-755.	1.3	27

#	ARTICLE	IF	CITATIONS
101	Tissue Repair and Regeneration. , 2008, , 333-366.		0
102	Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: A One-year Prospective Study. American Journal of Ophthalmology, 2008, 145, 249-256.e2.	1.7	188
103	Treatment of Neovascular Age-related Macular Degeneration with Intravitreal Bevacizumab: Efficacy of Three Consecutive Monthly Injections. American Journal of Ophthalmology, 2008, 146, 91-95.	1.7	37
104	Effect of Bevacizumab on Human Corneal Endothelial Cells: A Six-month Follow-up Study. American Journal of Ophthalmology, 2008, 146, 688-691.e2.	1.7	35
105	Acute Intraocular Inflammation after Intravitreal Injections of Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. Ophthalmology, 2008, 115, 1911-1915.e1.	2.5	108
106	Anti-vascular Endothelial Growth Factor Pharmacotherapy for Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 1837-1846.	2.5	132
107	Comparison of Multiple Reduced-dose and Standard Light Application in Photodynamic Therapy in an Animal Model of Choroidal Neovascularization. Journal of the Chinese Medical Association, 2008, 71, 135-142.	0.6	4
108	Shall we use Avastin [®] or Lucentis [®] for ocular neovascularization?. Acta Ophthalmologica, 2008, 86, 352-355.	0.6	6
110	Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. Canadian Journal of Ophthalmology, 2008, 43, 576-580.	0.4	17
111	Pharmacotherapy of age-related macular degeneration. Expert Opinion on Pharmacotherapy, 2008, 9, 3045-3052.	0.9	10
112	Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology, 2008, 92, 356-360.	2.1	68
113	Slitlamp-optical Coherence Tomography-guided Needling of Failing Filtering Blebs. JAMA Ophthalmology, 2008, 126, 284.	2.6	3
114	Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2008, 92, 70-73.	2.1	232
115	Emerging Roles for the CD36 Scavenger Receptor as a Potential Therapeutic Target for Corneal Neovascularization. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2008, 8, 255-272.	0.6	8
116	Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion. British Journal of Ophthalmology, 2008, 92, 1424-1428.	2.1	17
117	Automatic segmentation in three-dimensional analysis of fibrovascular pigment epithelial detachment using high-definition optical coherence tomography. British Journal of Ophthalmology, 2008, 92, 197-203.	2.1	71
118	Ranibizumab for neovascular age-related macular degeneration. American Journal of Health-System Pharmacy, 2008, 65, 1805-1814.	0.5	25
119	Effects of Bevacizumab (Avastin) on Retinal Cells in Organotypic Culture. , 2008, 49, 3164.		38

#	ARTICLE	IF	CITATIONS
120	A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2008, 92, 1636-1641.	2.1	54
121	An Ethical View of the Ranibizumab and Bevacizumab Controversy. <i>JAMA Ophthalmology</i> , 2008, 126, 286.	2.6	2
122	Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. <i>British Journal of Ophthalmology</i> , 2008, 92, 518-522.	2.1	171
124	Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2008, 92, 210-212.	2.1	26
125	Intravitreal Bevacizumab and Triamcinolone Acetonide Combination Therapy for Exudative Neovascular Age-Related Macular Degeneration: Short-Term Optical Coherence Tomography Results. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2008, 24, 15-24.	0.6	16
126	Verteporfin photodynamic therapy in the age of antiangiogenic therapy. <i>Expert Review of Ophthalmology</i> , 2008, 3, 365-383.	0.3	1
128	ANTIANGIOGENIC THERAPY WITH INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY. <i>Retina</i> , 2008, 28, S19-S25.	1.0	126
129	INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION. <i>Retina</i> , 2008, 28, 689-695.	1.0	43
130	REPEATED INTRAVITREAL INJECTION OF BEVACIZUMAB FOR CLINICALLY SIGNIFICANT DIABETIC MACULAR EDEMA. <i>Retina</i> , 2008, 28, 1314-1318.	1.0	28
131	INCIDENCE OF ACUTE ONSET ENDOPHTHALMITIS FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION. <i>Retina</i> , 2008, 28, 564-567.	1.0	145
132	SURVEILLANCE FOR POTENTIAL ADVERSE EVENTS ASSOCIATED WITH THE USE OF INTRAVITREAL BEVACIZUMAB FOR RETINAL AND CHOROIDAL VASCULAR DISEASE. <i>Retina</i> , 2008, 28, 1151-1158.	1.0	69
133	CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA. <i>Retina</i> , 2008, 28, 1308-1313.	1.0	77
134	RATE OF MICROBIOLOGICAL CONTAMINATION IN VIALS OF BEVACIZUMAB USED FOR MULTIPLE INTRAVITREAL INJECTIONS. <i>Retinal Cases and Brief Reports</i> , 2008, 2, 133-135.	0.3	2
135	The cost of vision for vitreoretinal interventions. <i>Current Opinion in Ophthalmology</i> , 2008, 19, 195-201.	1.3	2
136	CHANGES IN RETINAL SENSITIVITY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AFTER SYSTEMIC BEVACIZUMAB (AVASTIN) THERAPY. <i>Retina</i> , 2008, 28, 682-688.	1.0	31
137	LONG-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR THE MANAGEMENT OF CENTRAL RETINAL VEIN OCCLUSION. <i>Retina</i> , 2008, 28, 1325-1337.	1.0	39
138	INTRAVITREAL BEVACIZUMAB (AVASTIN) PREVENTION OF PANRETINAL PHOTOCOAGULATION-INDUCED COMPLICATIONS IN PATIENTS WITH SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2008, 28, 1319-1324.	1.0	45
139	SHORT-TERM EFFICACY AND SAFETY OF INTRAVITREAL RANIBIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2008, 28, 1117-1123.	1.0	78

#	ARTICLE	IF	CITATIONS
140	INTRAVITREAL BEVACIZUMAB (AVASTIN) AND RANIBIZUMAB (LUCENTIS) FOR CHOROIDAL NEOVASCULARIZATION OVERLYING CHOROIDAL OSTEOMA. Retinal Cases and Brief Reports, 2008, 2, 18-20.	0.3	15
141	Treatment of age-related macular degeneration: focus on ranibizumab. Clinical Ophthalmology, 2008, 2, 1.	0.9	40
142	Current and emerging therapies for the treatment of age-related macular degeneration. Clinical Ophthalmology, 2008, 2, 377.	0.9	46
143	Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration. Clinical Ophthalmology, 2008, 2, 727.	0.9	9
144	Treatment of neovascular age-related macular degeneration: Current therapies. Clinical Ophthalmology, 2009, 3, 175.	0.9	28
145	Short-term Safety and Efficacy of Intravitreal Bavacizumab Injection. Journal of Korean Ophthalmological Society, 2009, 50, 219.	0.0	4
146	Age-related macular degeneration: current treatments. Clinical Ophthalmology, 2009, 3, 155.	0.9	43
147	Short-term Efficacy of Intravitreal Bavacizumab for Polypoidal Choroidal Vasculopathy. Journal of Korean Ophthalmological Society, 2009, 50, 51.	0.0	4
148	Short-term Efficacy of Intravitreal Ranibizumab for Myopic Choroidal Neovascularization. Journal of Korean Ophthalmological Society, 2009, 50, 1027.	0.0	4
149	Effects and Prognostic Factors of Intravitreal Bevacizumab Injection on Choroidal Neovascularization from Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2009, 50, 202.	0.0	7
150	Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?. Clinical Interventions in Aging, 2009, 4, 457.	1.3	21
152	Age-Related Eye Diseases. , 0, , 469-484.		0
153	Exudative Age-Related Macular Degeneration: Current Therapies and Potential Treatments. Clinical Medicine Therapeutics, 2009, 1, CMT.S2225.	0.1	0
154	Serous Retinal Detachment Following Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection. Korean Journal of Ophthalmology: KJO, 2009, 23, 124.	0.5	1
155	Anti-Vascular Endothelial Growth Factor Activity in the Bevacizumab and Triamcinolone Acetonide Combination for Intravitreal Use. European Journal of Ophthalmology, 2009, 19, 842-847.	0.7	3
156	rAAV.sFlt-1 Gene Therapy Achieves Lasting Reversal of Retinal Neovascularization in the Absence of a Strong Immune Response to the Viral Vector. , 2009, 50, 4279.		43
157	Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. British Journal of Ophthalmology, 2009, 93, 150-154.	2.1	93
158	Treatment of retinal diseases with VEGF antagonists. Progress in Brain Research, 2009, 175, 253-267.	0.9	43

#	ARTICLE	IF	CITATIONS
159	Simultaneous Intravitreal and Intracameral Injection of Bevacizumab (Avastin) in Neovascular Glaucoma. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 259-264.	0.6	12
160	Novel Drug Delivery Systems for Retinal Diseases. <i>Ophthalmic Research</i> , 2009, 41, 124-135.	1.0	53
161	Intravitreal Bevacizumab versus Triamcinolone Acetonide for Exudative Age-Related Macular Degeneration. <i>Ophthalmic Research</i> , 2009, 41, 21-27.	1.0	20
162	Transient Bevacizumab (Avastin)-Induced Alterations in Rat Eyes. <i>Ophthalmic Research</i> , 2009, 41, 28-35.	1.0	9
163	Large Subretinal Haemorrhage following Change from Intravitreal Bevacizumab to Ranibizumab. <i>Ophthalmologica</i> , 2009, 223, 279-282.	1.0	22
164	Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab Injection for the Management of Polypoidal Choroidal Vasculopathy. <i>Ophthalmologica</i> , 2009, 223, 85-92.	1.0	45
165	Current Trends in Age-Related Macular Degeneration. <i>Postgraduate Medicine</i> , 2009, 121, 136-140.	0.9	0
166	Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets. <i>Current Medicinal Chemistry</i> , 2009, 16, 94-112.	1.2	237
167	Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. <i>British Journal of Ophthalmology</i> , 2009, 93, 589-593.	2.1	66
168	Age-related maculopathy "Linking aetiology and pathophysiological changes to the ischaemia hypothesis. <i>Progress in Retinal and Eye Research</i> , 2009, 28, 63-86.	7.3	116
169	A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 1-11.	1.0	96
170	Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 735-743.	1.0	83
171	One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 899-906.	1.0	31
173	Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up. <i>Japanese Journal of Ophthalmology</i> , 2009, 53, 125-130.	0.9	9
174	Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. <i>International Ophthalmology</i> , 2009, 29, 349-357.	0.6	24
175	Pattern electroretinographic results after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. <i>Documenta Ophthalmologica</i> , 2009, 119, 37-42.	1.0	4
178	Bevacizumab: a new hope?. <i>Eye</i> , 2009, 23, 1755-1757.	1.1	0
179	Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. <i>Eye</i> , 2009, 23, 694-702.	1.1	47

#	ARTICLE	IF	CITATIONS
180	Verteporfin therapy in occult with no classic CNV due to AMD: results of the Photodynamic Therapy in Occult-Only Lesions study. <i>Eye</i> , 2009, 23, 791-800.	1.1	1
181	Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration. <i>Eye</i> , 2009, 23, 453-460.	1.1	19
182	The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. <i>Eye</i> , 2009, 23, 1714-1718.	1.1	61
183	Should avastin be used to treat age-related macular degeneration in the NHS? â€œ Yes. <i>Eye</i> , 2009, 23, 1247-1249.	1.1	1
184	Bevacizumab (Avastin) for the Treatment of Ocular Disease. <i>Survey of Ophthalmology</i> , 2009, 54, 372-400.	1.7	125
185	Applying the CONSORT and STROBE Statements to Evaluate the Reporting Quality of Neovascular Age-related Macular Degeneration Studies. <i>Ophthalmology</i> , 2009, 116, 286-296.e4.	2.5	70
186	Economic Implications of Current Age-Related Macular Degeneration Treatments. <i>Ophthalmology</i> , 2009, 116, 481-487.	2.5	27
187	Verteporfin Photodynamic Therapy Combined With Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, 747-755.e1.	2.5	83
188	Systemic Adverse Events after Bevacizumab. <i>Ophthalmology</i> , 2009, 116, 1226-1226.e1.	2.5	19
189	Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. <i>Ophthalmology</i> , 2009, 116, 1488-1497.e1.	2.5	125
190	Association of Retinal Sensitivity and Morphology during Antiangiogenic Treatment of Retinal Vein Occlusion over One Year. <i>Ophthalmology</i> , 2009, 116, 2415-2421.	2.5	47
191	Introduction: Understanding the Role of Angiogenesis and Antiangiogenic Agents in Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, S1-S7.	2.5	166
192	Outcome Measures to Assess Efficacy of Treatments for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, S8-S14.	2.5	6
193	Intravitreal Bevacizumab for Diabetic Macular Edema Associated With Severe Capillary Loss: One-Year Results of a Pilot Study. <i>American Journal of Ophthalmology</i> , 2009, 147, 1022-1030.e5.	1.7	37
194	Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study. <i>American Journal of Ophthalmology</i> , 2009, 148, 59-65.e1.	1.7	71
195	Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial. <i>American Journal of Ophthalmology</i> , 2009, 148, 875-882.e1.	1.7	66
196	Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration. <i>Drugs and Aging</i> , 2009, 26, 295-320.	1.3	27
197	Retinal Angiography and Optical Coherence Tomography. , 2009, , .		18

#	ARTICLE	IF	CITATIONS
198	The Effects of Intravitreal Ophthalmic Medications on Intraocular Pressure. <i>Seminars in Ophthalmology</i> , 2009, 24, 100-105.	0.8	21
199	Effect of Intravitreal Injection of High-Dose Bevacizumab in Monkey Eyes. , 2009, 50, 4905.		38
200	Efficacy of intravitreal bevacizumab (Avastin [®]) therapy for early and advanced neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2009, 87, 611-617.	0.6	24
201	Intravitreal bevacizumab (Avastin [®]) for neovascular age-related macular degeneration in treatment-naïve patients. <i>Acta Ophthalmologica</i> , 2009, 87, 714-719.	0.6	24
202	Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2009, 87, 736-740.	0.6	26
203	Effect of intravitreal bevacizumab (Avastin [®]) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6 and 12 month results. <i>Acta Ophthalmologica</i> , 2010, 88, 594-600.	0.6	25
204	Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). <i>British Journal of Ophthalmology</i> , 2009, 93, 457-462.	2.1	111
205	VERTEPORFIN COMBINATION REGIMENS IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 133-148.	1.0	30
206	PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION. <i>Retina</i> , 2009, 29, 699-703.	1.0	150
207	INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS. <i>Retina</i> , 2009, 29, 875-912.	1.0	215
208	COMPARISON OF INTRAVITREAL BEVACIZUMAB FOLLOWED BY RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 1067-1073.	1.0	45
209	SHORT-TERM EFFECTIVENESS OF INTRAVITREAL BEVACIZUMAB VERSUS RANIBIZUMAB INJECTIONS FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 1235-1241.	1.0	24
210	Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 158-165.	1.3	110
211	SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR THE MANAGEMENT OF BRANCH AND HEMIRETINAL VEIN OCCLUSION. <i>Retina</i> , 2009, 29, 913-925.	1.0	54
212	INTRAVITREAL RANIBIZUMAB FOR THE PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA. <i>Retina</i> , 2009, 29, 750-756.	1.0	91
213	BEVACIZUMAB (AVASTIN) THERAPY FOR IDIOPATHIC MACULAR TELANGIECTASIA TYPE II. <i>Retina</i> , 2009, 29, 27-32.	1.0	75
214	SAFETY OF REPEAT INTRAVITREAL INJECTIONS OF BEVACIZUMAB VERSUS RANIBIZUMAB. <i>Retina</i> , 2009, 29, 313-318.	1.0	114
215	Anti-VEGF Therapy in Proliferative Diabetic Retinopathy. <i>International Ophthalmology Clinics</i> , 2009, 49, 95-107.	0.3	30

#	ARTICLE	IF	CITATIONS
216	VISUAL OUTCOMES AND GROWTH FACTOR CHANGES OF TWO DOSAGES OF INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 1218-1226.	1.0	24
217	TOXIC VITREITIS OUTBREAK AFTER INTRAVITREAL INJECTION. <i>Retina</i> , 2010, 30, 332-338.	1.0	53
218	INTRAVITREAL RANIBIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2010, 30, 407-412.	1.0	82
219	TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY WITH INTRAVITREAL BEVACIZUMAB (AVASTIN). <i>Retina</i> , 2010, 30, S24-S31.	1.0	69
220	INTRAVITREAL ANTI-VEGF VERSUS PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2010, 30, 418-424.	1.0	63
221	INTRAVITREAL BEVACIZUMAB IN VASCULAR PIGMENT EPITHELIUM DETACHMENT AS A RESULT OF SUBFOVEAL OCCULT CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2010, 30, 1420-1425.	1.0	29
222	INTRAVITREAL BEVACIZUMAB INJECTION FOR CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2010, 30, 100-106.	1.0	121
223	In Vitro Effects of Antivascular Endothelial Growth Factors on Cultured Human Trabecular Meshwork Cells. <i>Journal of Glaucoma</i> , 2010, 19, 437-441.	0.8	52
224	INTRAVITREAL BEVACIZUMAB DURING PREGNANCY. <i>Retina</i> , 2010, 30, 1405-1411.	1.0	83
225	Full Macular Translocation for Choroidal Neovascularization in the Era of Intravitreal Pharmacological Therapy. <i>Retina</i> , 2010, 30, 1739-1743.	1.0	3
226	The effects of intravitreally injected bevacizumab on the retina and retina pigment epithelium: experimental in-vivo electron microscopic study in intact versus vitrectomized eyes. <i>Open Medicine (Poland)</i> , 2010, 5, 745-751.	0.6	1
228	Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 1713-1718.	1.0	52
229	Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. <i>Japanese Journal of Ophthalmology</i> , 2010, 54, 124-128.	0.9	7
230	Treatment of age-related macular degeneration: Beyond VEGF. <i>Japanese Journal of Ophthalmology</i> , 2010, 54, 523-528.	0.9	29
231	Protein delivery for retinal diseases: From basic considerations to clinical applications. <i>Progress in Retinal and Eye Research</i> , 2010, 29, 443-465.	7.3	83
232	Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. <i>Eye</i> , 2010, 24, 816-824.	1.1	38
233	Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. <i>Eye</i> , 2010, 24, 1708-1715.	1.1	71
234	Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology. <i>Eye</i> , 2010, 24, 1320-1324.	1.1	6

#	ARTICLE	IF	CITATIONS
235	Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. <i>Eye</i> , 2010, 24, 1344-1351.	1.1	4
236	Short-term Effects of Intravitreal Bevacizumab Injection and Macular Edema Patterns in Branch Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2010, 51, 379.	0.0	4
237	Long-Term Tolerability and Serum Concentration of Bevacizumab (Avastin) when Injected in Newborn Rabbit Eyes. , 2010, 51, 3701.		34
238	Three-Monthly Intravitreal Bevacizumab Injections for Neovascular Age-Related Macular Degeneration: Short-Term Visual Acuity Results. <i>European Journal of Ophthalmology</i> , 2010, 20, 740-744.	0.7	5
239	The macular threshold protocol of the Humphrey visual field analyzer: a superior functional outcome of intravitreal bevacizumab for the treatment of neovascular age-related macular degeneration. <i>Arquivos Brasileiros De Oftalmologia</i> , 2010, 73, 111-115.	0.2	2
240	Aging and Disorders of the Eye. , 2010, , 810-821.		6
241	Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor. <i>Clinical Ophthalmology</i> , 2010, 4, 275.	0.9	16
242	Choroidal neovascularization secondary to inflammation, infection, and myopia. , 2010, , 162-169.		1
243	Subconjunctival Bevacizumab as an Adjunct to Trabeculectomy in Eyes with Refractory Glaucoma: A Case Series. <i>Korean Journal of Ophthalmology: KJO</i> , 2010, 24, 47.	0.5	24
244	Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?. <i>Clinical Ophthalmology</i> , 2010, 4, 307.	0.9	8
245	Comparative Review of Ranibizumab versus Bevacizumab in the Treatment of Neovascular Age-related Macular Degeneration. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S2226.	0.4	0
246	SYSTEMIC BEVACIZUMAB LEADS TO RESOLUTION OF DIABETIC MACULAR EDEMA. <i>Retinal Cases and Brief Reports</i> , 2010, 4, 297-299.	0.3	0
247	Bevacizumab vs Photodynamic Therapy for Choroidal Neovascularization in Multifocal Choroiditis. <i>JAMA Ophthalmology</i> , 2010, 128, 1100.	2.6	38
248	Update on combination therapy in wet age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2010, 5, 681-688.	0.3	1
249	Intravitreal Bevacizumab in Treatment of Idiopathic Persistent Central Serous Chorioretinopathy: A Prospective, Controlled Clinical Study. <i>Current Eye Research</i> , 2010, 35, 91-98.	0.7	88
250	Effect of intravitreal bevacizumab (Avastin®) in the fellow eye of a patient with bilateral exudative age related macular degeneration. <i>Scottish Medical Journal</i> , 2010, 55, 58-58.	0.7	0
251	Non-arteritic ischemic optic neuropathy followed by intravitreal bevacizumab injection: Is there an association?. <i>Indian Journal of Ophthalmology</i> , 2010, 58, 349.	0.5	13
252	Late posterior subluxation of rollable intraocular lens after an uneventful microphacoemulsification cataract surgery. <i>Indian Journal of Ophthalmology</i> , 2010, 58, 350.	0.5	5

#	ARTICLE	IF	CITATIONS
253	Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: Short-term results. <i>Indian Journal of Ophthalmology</i> , 2010, 58, 291.	0.5	24
254	Acute Vision Loss after Intravitreal Injection of Bevacizumab (Avastin) Associated with Ocular Ischemic Syndrome. <i>Ophthalmologica</i> , 2010, 224, 86-89.	1.0	36
255	Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration. <i>Developments in Ophthalmology</i> , 2010, 46, 21-38.	0.1	15
256	Ocular safety profile and intraocular pharmacokinetics of an antagonist of EphB4/EphrinB2 signalling. <i>British Journal of Ophthalmology</i> , 2010, 94, 1668-1673.	2.1	8
257	Treatment of Choroidal Neovascularization in High Myopia. <i>Current Drug Targets</i> , 2010, 11, 630-644.	1.0	21
258	Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. <i>BMJ: British Medical Journal</i> , 2010, 340, c2459-c2459.	2.4	186
259	Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2010, 128, 1273.	2.6	181
260	Age related macular degeneration. <i>BMJ: British Medical Journal</i> , 2010, 340, c981-c981.	2.4	75
261	Anti-VEGF agents for age-related macular degeneration. <i>Expert Opinion on Therapeutic Patents</i> , 2010, 20, 103-118.	2.4	31
262	Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy,) <i>Tj ETQq1 1 0.784314 rgBT /Ove</i> 45, 36-40.	0.4	24
263	Intravitreal Bevacizumab and Ranibizumab for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2010, 117, 298-302.	2.5	90
264	Combined Photodynamic Therapy With Verteporfin and Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy. <i>American Journal of Ophthalmology</i> , 2010, 149, 947-954.e1.	1.7	65
265	Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2010, 88, 630-634.	0.6	16
266	Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin) in neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2010, 88, 641-645.	0.6	47
267	Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization. <i>Acta Ophthalmologica</i> , 2010, 88, e305-10.	0.6	9
268	Testing toxicity of multiple intravitreal injections of bevacizumab in rabbit eyes. <i>Canadian Journal of Ophthalmology</i> , 2010, 45, 386-392.	0.4	19
269	Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary. <i>Canadian Journal of Ophthalmology</i> , 2010, 45, 501-508.	0.4	8
270	Effects of Pegaptanib Sodium on Retinal Function in Isolated Perfused Vertebrate Retina. <i>Current Eye Research</i> , 2010, 35, 248-254.	0.7	5

#	ARTICLE	IF	CITATIONS
271	Severe Corneal Changes following Intravitreal Injection of Bevacizumab. <i>Ocular Immunology and Inflammation</i> , 2010, 18, 268-274.	1.0	21
272	Radiation therapy in the treatment of exudative age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2011, 6, 323-337.	0.3	1
273	The Effect of Intravitreal Injection of Bevacizumab on Retinal Circulation in Patients with Neovascular Macular Degeneration. , 2011, 52, 7400.		38
274	Neovascular Age-Related Macular Degeneration. <i>BioDrugs</i> , 2011, 25, 171-189.	2.2	2
275	Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. <i>British Journal of Ophthalmology</i> , 2011, 95, 1111-1114.	2.1	195
276	Management of Neovascular AMD. , 2011, , 79-98.		0
277	Drug Product Development for the Back of the Eye. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011, , .	0.2	13
278	Pharmacotherapy for Neovascular Age-Related Macular Degeneration: An Analysis of the 100% 2008 Medicare Fee-For-Service Part B Claims File. <i>American Journal of Ophthalmology</i> , 2011, 151, 887-895.e1.	1.7	122
279	How the Comparison of Age-related Macular Degeneration Treatments Trial Results Will Impact Clinical Care. <i>American Journal of Ophthalmology</i> , 2011, 152, 509-514.	1.7	18
280	Retinal pigment epithelial expression of complement regulator CD46 is altered early in the course of geographic atrophy. <i>Experimental Eye Research</i> , 2011, 93, 413-423.	1.2	91
281	Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease. <i>Survey of Ophthalmology</i> , 2011, 56, 95-113.	1.7	257
282	Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization. <i>Acta Ophthalmologica</i> , 2011, 89, 218-221.	0.6	9
283	Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. <i>Acta Ophthalmologica</i> , 2011, 89, 647-653.	0.6	20
284	Increased electroretinogram <i>a</i> -wave amplitude after intravitreal bevacizumab injection for neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2011, 89, e269-73.	0.6	13
285	Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma. <i>Clinical Ophthalmology</i> , 2011, 5, 841.	0.9	13
286	Multifocal Electroretinogram Findings after Intravitreal Bevacizumab Injection in Choroidal Neovascularization of Age-Related Macular Degeneration. <i>Korean Journal of Ophthalmology: KJO</i> , 2011, 25, 161.	0.5	8
287	Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. <i>Korean Journal of Ophthalmology: KJO</i> , 2011, 25, 231.	0.5	8
288	Intravitreal Injection of Bevacizumab Induces Inflammatory Alterations in a Uveitis Experimental Model. <i>European Journal of Ophthalmology</i> , 2011, 21, 427-433.	0.7	6

#	ARTICLE	IF	CITATIONS
289	Combined Intravitreal Bevacizumab and Trabeculectomy With Mitomycin C Versus Trabeculectomy With Mitomycin C Alone for Neovascular Glaucoma. <i>Journal of Glaucoma</i> , 2011, 20, 196-201.	0.8	64
290	INTRAVITREAL BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION. <i>Retina</i> , 2011, 31, 1856-1862.	1.0	46
291	Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration. <i>Current Drug Targets</i> , 2011, 12, 149-172.	1.0	56
292	A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. <i>Retina</i> , 2011, 31, 1449-1469.	1.0	131
293	AltersabhÄngige Makuladegeneration. , 2011, , .		3
295	Intravitreal Bevacizumab Injection Therapy for Persistent Macular Edema After Idiopathic Macular Epiretinal Membrane Surgery. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 287-292.	0.6	14
296	INTRAVITREAL BEVACIZUMAB AND RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO ENDOGENOUS ENDOPHTHALMITIS. <i>Retinal Cases and Brief Reports</i> , 2011, 5, 229-232.	0.3	2
297	Vitreous Web after Pars Plana Vitrectomy and Bevacizumab with Fluid-Air Exchange. <i>Seminars in Ophthalmology</i> , 2011, 26, 25-27.	0.8	7
298	Intravitreal Bevacizumab in Refractory Neovascular Glaucoma. <i>JAMA Ophthalmology</i> , 2011, 129, 145.	2.6	34
299	Effects of Bevacizumab (Avastin®) on the Electroretinogram of Isolated Rat Retina. <i>Ophthalmic Research</i> , 2011, 46, 145-151.	1.0	2
300	Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration. <i>Current Vascular Pharmacology</i> , 2011, 9, 629-646.	0.8	39
301	Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling. , 2011, 52, 1023.		166
302	Comparison of Long-Acting Bevacizumab Formulations in the Treatment of Choroidal Neovascularization in a Rat Model. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 219-224.	0.6	57
303	The past, present, and future of exudative age-related macular degeneration treatment. <i>Middle East African Journal of Ophthalmology</i> , 2012, 19, 43.	0.5	15
304	INTRAOCULAR BEVACIZUMAB LEVELS 24 HOURS AFTER INTRAVITREAL INJECTION IN A NORMAL EYE. <i>Retinal Cases and Brief Reports</i> , 2012, 6, 65-68.	0.3	2
305	An Update on Intravitreal Injections for Macular Diseases. <i>Asia-Pacific Journal of Ophthalmology</i> , 2012, 1, 43-50.	1.3	0
306	Diabetic Retinopathy: Current and New Treatment Options. <i>Current Diabetes Reviews</i> , 2012, 8, 32-41.	0.6	30
308	One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation. <i>Japanese Journal of Ophthalmology</i> , 2012, 56, 599-607.	0.9	4

#	ARTICLE	IF	CITATIONS
309	Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs. Canadian Journal of Ophthalmology, 2012, 47, 165-169.	0.4	9
310	Bevacizumab for Neovascular Age-related Macular Degeneration in China. Ophthalmology, 2012, 119, 2087-2093.	2.5	18
311	Optical Coherence Tomography Grading Reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology, 2012, 119, 2549-2557.	2.5	59
312	Phacoemulcification with Intravitreal Bevacizumab Injection in Patients with Cataract and Coexisting Diabetic Retinopathy: Prospective Randomized Study. Journal of Ocular Pharmacology and Therapeutics, 2012, 28, 212-218.	0.6	16
313	Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration. Ophthalmology, 2012, 119, 1399-1411.	2.5	724
314	Near-Infrared Autofluorescence in Patients With Idiopathic Submacular Choroidal Neovascularization. American Journal of Ophthalmology, 2012, 153, 314-319.	1.7	16
315	Bevacizumab for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen: Clinical and Economic Impact. American Journal of Ophthalmology, 2012, 153, 468-473.e1.	1.7	71
316	Delay to Treatment and Visual Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration. American Journal of Ophthalmology, 2012, 153, 678-686.e2.	1.7	119
317	Treatment Patterns for Neovascular Age-Related Macular Degeneration: Analysis of 284 380 Medicare Beneficiaries. American Journal of Ophthalmology, 2012, 153, 1116-1124.e1.	1.7	61
318	An Outbreak of Streptococcus Endophthalmitis After Intravitreal Injection of Bevacizumab. American Journal of Ophthalmology, 2012, 153, 204-208.e1.	1.7	142
319	Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and Intravitreal Biologics for Ocular Inflammation. American Journal of Ophthalmology, 2012, 154, 429-435.e2.	1.7	15
320	Proteomic Analysis of the Aqueous Humor in Age-related Macular Degeneration (AMD) Patients. Journal of Proteome Research, 2012, 11, 4034-4043.	1.8	52
321	Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy. Arquivos Brasileiros De Oftalmologia, 2012, 75, 273-276.	0.2	7
322	Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clinical Ophthalmology, 2012, 6, 1149.	0.9	21
323	Comparison of Two Doses of IVB and Prognostic Factor on Myopic CNV : 1-Year Outcome. Journal of Korean Ophthalmological Society, 2012, 53, 1807.	0.0	1
324	Age-related macular degeneration with choroidal neovascularization in the setting of pre-existing geographic atrophy and ranibizumab treatment. Analysis of a case series and revision paper. Revista Brasileira De Oftalmologia, 2012, 71, 407-411.	0.1	1
325	The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model. Clinical Ophthalmology, 2012, 6, 61.	0.9	9
326	Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nature Reviews Drug Discovery, 2012, 11, 541-559.	21.5	275

#	ARTICLE	IF	CITATIONS
327	Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. <i>Journal of Evaluation in Clinical Practice</i> , 2012, 18, 247-255.	0.9	36
328	Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. <i>Acta Ophthalmologica</i> , 2012, 90, 61-67.	0.6	32
329	Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model. <i>Acta Ophthalmologica</i> , 2012, 90, 564-570.	0.6	30
330	The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. <i>Journal of Neuro-Oncology</i> , 2012, 106, 81-88.	1.4	17
331	Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 1355-1360.	1.0	8
332	Acute bacterial endophthalmitis after intravitreal bevacizumab injection: Case report and literature review. <i>Saudi Journal of Ophthalmology</i> , 2013, 27, 55-57.	0.3	6
333	Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. <i>Lancet, The</i> , 2013, 382, 1258-1267.	6.3	623
334	Reversible myocardial dysfunction following intraocular bevacizumab administration. <i>Journal of Cardiovascular Disease Research (discontinued)</i> , 2013, 4, 58-60.	0.1	3
335	Serum Levels of Intravitreal Bevacizumab After Vitrectomy, Lensectomy and Non-Surgical Controls. <i>Current Eye Research</i> , 2013, 38, 761-766.	0.7	11
336	Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study. <i>Investigational New Drugs</i> , 2013, 31, 59-65.	1.2	15
337	Vascular endothelial growth factor and its inhibitor in age-related macular degeneration. <i>Taiwan Journal of Ophthalmology</i> , 2013, 3, 128-133.	0.3	3
338	Diffusion of Technologies for the Care of Older Adults With Exudative Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2013, 155, 688-696.e2.	1.7	20
339	Streptococcus Endophthalmitis Outbreak after Intravitreal Injection of Bevacizumab: One-Year Outcomes and Investigative Results. <i>Ophthalmology</i> , 2013, 120, 1448-1453.	2.5	62
340	Combination Therapies for the Treatment of AMD. , 2013, , 247-261.		1
342	Intravitreal aflibercept for neovascular age-related macular degeneration. <i>Immunotherapy</i> , 2013, 5, 121-130.	1.0	9
343	The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveal choroidal neovascularisation. <i>Vojnosanitetski Pregled</i> , 2013, 70, 660-663.	0.1	2
344	Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2013, 24, 205-212.	1.3	26
345	Intrasilicone Bevacizumab Injection for Iris Neovascularization after Vitrectomy for Proliferative Diabetic Retinopathy. <i>Ophthalmic Research</i> , 2013, 49, 20-24.	1.0	16

#	ARTICLE	IF	CITATIONS
346	Quality of bevacizumab compounded for intravitreal administration. <i>Eye</i> , 2013, 27, 1090-1097.	1.1	38
348	Acute Vision Loss Associated with Retinal Circulatory Disturbances After Intravitreal Injection of Bevacizumab. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 79-83.	0.6	6
349	The Results of Switching between 2 Anti-VEGF Drugs, Bevacizumab and Ranibizumab, in the Treatment of Neovascular Age-related Macular Degeneration. <i>European Journal of Ophthalmology</i> , 2013, 23, 553-557.	0.7	23
350	The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing. <i>Clinical Ophthalmology</i> , 2013, 7, 185.	0.9	17
351	Anti-VEGF-refractory Exudative Age-related Macular Degeneration: Differential Response According to Features on Optical Coherence Tomography. <i>Korean Journal of Ophthalmology: KJO</i> , 2013, 27, 425.	0.5	19
352	Vitreous Web after Pars Plana Vitrectomy and Bevacizumab Injection. <i>Journal of Korean Ophthalmological Society</i> , 2014, 55, 780.	0.0	0
353	Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab. <i>Clinical Ophthalmology</i> , 2014, 8, 743.	0.9	8
354	Critical evaluation of the off-label indication and of the risks associated to the use of multi-dose vials on the treatment of age-related macular degeneration. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2014, 50, 63-72.	1.2	2
355	Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy. <i>Clinical Ophthalmology</i> , 2014, 8, 485.	0.9	13
356	Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 699-706.	1.1	36
357	Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration: Clinical Comparison. <i>Ophthalmologica</i> , 2014, 232, 149-155.	1.0	8
359	Trophic factors in the pathogenesis and therapy for retinal degenerative diseases. <i>Survey of Ophthalmology</i> , 2014, 59, 134-165.	1.7	93
360	SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS. <i>Retina</i> , 2015, 35, 841-858.	1.0	71
361	INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2015, 35, 1992-2000.	1.0	5
362	22 anti-vascular endothelial growth factor (anti-VEGF) therapy Optical Coherence Tomography and Anti-Vascular Endothelial Growth Factor Therapy. , 2015, , .		0
363	Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5397.	2.0	55
364	Peripapillary Choroidal Neovascularization Associated with Optic Nerve Head Drusen Treated with Anti-VEGF Agents. <i>Case Reports in Ophthalmology</i> , 2015, 6, 51-55.	0.3	10
365	Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015, 122, 1348-1355.	2.5	11

#	ARTICLE	IF	CITATIONS
366	Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice. <i>Ophthalmologica</i> , 2015, 233, 155-161.	1.0	46
367	The other CNVM: A review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents. <i>Survey of Ophthalmology</i> , 2015, 60, 204-215.	1.7	22
368	Evaluation of Intracameral Injection of Ranibizumab and Bevacizumab on the Corneal Endothelium by Scanning Electron Microscopy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2015, 31, 100-105.	0.6	7
369	Role of Subconjunctival Bevacizumab as an Adjuvant to Primary Trabeculectomy. <i>Journal of Glaucoma</i> , 2015, 24, 1-8.	0.8	44
370	Bevacizumab modulates the process of fibrosis <i>in vitro</i> . <i>Clinical and Experimental Ophthalmology</i> , 2015, 43, 173-179.	1.3	29
371	Vascular Endothelial Growth Factor Receptor 2 Antibody, BC001, Attenuates Laser-Induced Choroidal Neovascularization in Rhesus Monkeys (<i>Macaca mulatta</i>). <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2015, 31, 611-616.	0.6	6
372	Effects of intravitreal injection of bevacizumab on nitric oxide levels. <i>Eye</i> , 2015, 29, 436-442.	1.1	5
373	Is Spectral-Domain Optical Coherence Tomography Always Able to Detect the Anti-Vascular Endothelial Growth Factor Action on Neovascular Membrane. <i>Case Reports in Ophthalmology</i> , 2016, 7, 309-314.	0.3	0
374	Intravitreal bevacizumab for treatment of central serous chorioretinopathy. <i>Journal of Ophthalmic and Vision Research</i> , 2016, 11, 61.	0.7	16
375	Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2016, 27, 224-243.	1.3	14
376	Assessment of bevacizumab quality and stability in repackaged syringes for clinical use. <i>European Journal of Hospital Pharmacy</i> , 2016, 23, 343-347.	0.5	2
377	Long-Term Outcome and Recurrence of Idiopathic Choroidal Neovascularization Treated with Intravitreal Bevacizumab. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2016, 32, 431-436.	0.6	5
378	Anti-angiogenic Therapy for Retinal Disease. <i>Handbook of Experimental Pharmacology</i> , 2016, 242, 271-307.	0.9	38
379	Electroretinographic evaluations of retinal function before, just after and after intravitreal injections. <i>Scientific Reports</i> , 2016, 6, 31104.	1.6	4
380	Anti-VEGF and its impact on the outer retina: Retinal pigment epithelium tear after an injection of aflibercept in contralateral eye. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2016, 91, 245-249.	0.1	2
381	Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. <i>Eye</i> , 2016, 30, 805-811.	1.1	29
382	Anti-VEGF y sus consecuencias sobre la retina externa: rotura del epitelio pigmentario tras inyección de aflibercept en ojo contralateral. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2016, 91, 245-249.	0.1	3
383	Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. <i>Eye</i> , 2016, 30, 463-472.	1.1	62

#	ARTICLE	IF	CITATIONS
384	Effect of Regulatory Requirement for Patient-Specific Prescriptions for Off-Label Medications on the Use of Intravitreal Bevacizumab. <i>JAMA Ophthalmology</i> , 2016, 134, 45.	1.4	5
385	Complement pathway biomarkers and age-related macular degeneration. <i>Eye</i> , 2016, 30, 1-14.	1.1	30
386	A survey of current trends in computational drug repositioning. <i>Briefings in Bioinformatics</i> , 2016, 17, 2-12.	3.2	459
387	Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration. <i>Eye</i> , 2017, 31, 677-683.	1.1	11
388	Targeting endothelial metaflammation to counteract diabetes cardiovascular risk: Current and perspective therapeutic options. <i>Pharmacological Research</i> , 2017, 120, 226-241.	3.1	18
389	Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma. <i>Advances in Therapy</i> , 2017, 34, 378-395.	1.3	37
390	Cell Therapy for Ophthalmic Diseases. <i>Molecular and Translational Medicine</i> , 2017, , 249-279.	0.4	1
391	Développement galénique et analytique d'un collyre au bevacizumab 5 mg/mL: Étude de stabilité. <i>Pharmacien Hospitalier Et Clinicien</i> , 2017, 52, 325-331.	0.3	0
392	Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and <i>in vitro</i> toxicity evaluation. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2017, 45, 1397-1407.	1.9	91
393	Drug repurposing by integrated literature mining and drug-gene-disease triangulation. <i>Drug Discovery Today</i> , 2017, 22, 615-619.	3.2	45
394	Evaluation of effect of bevacizumab on central subfield macular thickness in the injected and contralateral (untreated) eye of patients with bilateral diabetic macular oedema. <i>BMJ Open Ophthalmology</i> , 2017, 2, e000102.	0.8	3
395	A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs. , 2017, 58, 3732.		11
396	Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis. , 2017, 58, 9.		55
397	Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 651-663.	1.0	24
398	Drug Repositioning by Integrating Known Disease-Gene and Drug-Target Associations in a Semi-supervised Learning Model. <i>Acta Biotheoretica</i> , 2018, 66, 315-331.	0.7	13
399	Intravitreal injection of the synthetic peptide LyeTx I b, derived from a spider toxin, into the rabbit eye is safe and prevents neovascularization in a chorio-allantoic membrane model. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2018, 24, 31.	0.8	7
400	Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy. <i>Biomedicine and Pharmacotherapy</i> , 2018, 107, 1056-1063.	2.5	49
401	Long-term Treatment Outcomes of Intravitreal Bevacizumab Treatment for Myopic Choroidal Neovascularization. <i>Journal of Korean Ophthalmological Society</i> , 2019, 60, 547.	0.0	2

#	ARTICLE	IF	CITATIONS
402	Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies. <i>BMJ Open Ophthalmology</i> , 2019, 4, e000257.	0.8	3
403	Characteristics of Perifoveal Exudative Vascular Anomalous Complex in Korean Patients. <i>Seminars in Ophthalmology</i> , 2019, 34, 353-358.	0.8	17
404	Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration. <i>Arquivos Brasileiros De Oftalmologia</i> , 2019, 82, 225-232.	0.2	4
405	Lessons Learned From Avastin and OCT – The Great, the Good, the Bad, and the Ugly: The LXXV Edward Jackson Memorial Lecture. <i>American Journal of Ophthalmology</i> , 2019, 204, 26-45.	1.7	10
406	Nanoscale delivery systems in treatment of posterior ocular neovascularization: strategies and potential applications. <i>Therapeutic Delivery</i> , 2019, 10, 737-747.	1.2	9
407	INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2019, 39, 648-655.	1.0	14
408	A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II. <i>Ophthalmology and Therapy</i> , 2020, 9, 35-75.	1.0	5
410	Immediate changes in blood pressure during intravitreal anti-VEGF agents' applications in exudative age-related macular degeneration patients. <i>International Ophthalmology</i> , 2020, 40, 2515-2522.	0.6	4
411	A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration. <i>BMC Ophthalmology</i> , 2020, 20, 21.	0.6	1
412	Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 1469.	0.5	3
413	Effect of intravitreal bevacizumab in the uninjected fellow eye of patients treated for retinal disorders. <i>Indian Journal of Clinical and Experimental Ophthalmology</i> , 2021, 7, 234-239.	0.1	0
414	Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options. <i>Cells</i> , 2021, 10, 1049.	1.8	61
415	Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4404.	1.8	12
416	Ä–rgÄ¼tsel Etik Ä°klim AlgÄ±sÄ±nÄ±n Ä¼alÄ±Ä¼yan SesiiliÄ¼i DavranÄ±Ä¼na Etkisinde Psikolojik GÄ¼venliÄ¼in AracÄ± Etkisi: VakÄ±f Ä±niversitelerine YÄ¼nelik Bir AraÄ¼tÄ±rma. <i>SelÄ¼uk Ä±niversitesi Sosyal Bilimler Meslek YÄ¼ksekokulu Dergisi</i> , 2021, 24, 57-70.	0.1	7
417	Endpoints selection in registration clinical trials and the needs of real-world clinical practice with the example of anti-VEGF therapy in neovascular age-related macular degeneration. <i>Ophthalmology Journal</i> , 2021, 14, 25-33.	0.1	0
418	Chitosan coated nanoparticles for efficient delivery of bevacizumab in the posterior ocular tissues via subconjunctival administration. <i>Carbohydrate Polymers</i> , 2021, 267, 118217.	5.1	27
419	Rodent Models of Oxygen-Induced Retinopathy. , 2008, , 57-80.		1
420	Protein Drug Delivery and Formulation Development. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011, , 409-448.	0.2	4

#	ARTICLE	IF	CITATIONS
421	INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH OR WITHOUT PRIOR TREATMENT WITH PHOTODYNAMIC THERAPY. <i>Retina</i> , 2010, 30, 85-92.	1.0	15
422	Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. <i>Acta Ophthalmologica</i> , 2007, 85, 563-565.	0.4	39
423	Treatment of choroidal neovascularization using intravitreal bevacizumab. <i>Acta Ophthalmologica</i> , 2007, 85, 526-534.	0.4	47
424	Intravitreal anti-inflammatory treatment for uveitis. <i>British Journal of Ophthalmology</i> , 2007, 91, 135-136.	2.1	5
425	Old drugs, new tricks. <i>BMJ: British Medical Journal</i> , 2011, 342, d741-d741.	2.4	46
426	Effect of different lens status on intraocular pressure elevation in patients treated with anti-vascular endothelial growth factor injections. <i>International Journal of Ophthalmology</i> , 2020, 13, 79-84.	0.5	7
427	Proteinuria and Renal Dysfunction after Intravitreal Injection of Bevacizumab in Patients with Diabetic Nephropathy: A Prospective Observational Study. <i>Galen</i> , 2018, 7, e1299.	0.6	6
428	Safety and Efficacy of Intravitreal Bevacizumab Followed by Pegaptanib Maintenance as a Treatment Regimen for Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2006, 37, 446-454.	0.4	31
429	Pegaptanib for Choroidal Neovascularization in Treatment-Naïve Exudative Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2007, 38, 371-377.	0.4	5
430	<i>Streptococcus mitis</i> Endophthalmitis Presenting as Frosted Branch Angiitis After Intravitreal Pegaptanib Sodium Injection. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2009, 40, 192-194.	0.4	19
431	Sustained Elevation in Intraocular Pressure Associated With Intravitreal Bevacizumab Injections. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2009, 40, 293-295.	0.4	109
432	Full Thickness Macular Hole Formation in a Patient with Cystoid Macular Edema Caused by CRVO Treated with Intravitreal Bevacizumab. <i>Ophthalmic Surgery, Lasers and Imaging</i> , 2010, , 1-4.	0.5	5
433	Ranibizumab for Exudative Age-Related Macular Degeneration in Eyes Previously Treated With Alternative Vascular Endothelial Growth Factor Inhibitors. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 182-189.	0.4	18
434	Intravitreal Bevacizumab for the Treatment of Refractory Diabetic Macular Edema. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 323-329.	0.4	25
435	Clinical Course of Choroidal Neovascularization Secondary to Angioid Streaks Treated with Intravitreal Bevacizumab. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 546-549.	0.4	13
436	Development of Subretinal Fibrosis After Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2011, 42, 6-11.	0.4	65
437	Uveitis Following Intravitreal Bevacizumab: A Non-Infectious Cluster. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2011, 42, 292-296.	0.4	35
438	Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits. <i>International Journal of Ophthalmology</i> , 2015, 8, 653-8.	0.5	22

#	ARTICLE	IF	CITATIONS
439	Bevacizumab: Off-label use in ophthalmology. Indian Journal of Ophthalmology, 2007, 55, 417.	0.5	58
440	Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian Journal of Ophthalmology, 2007, 55, 451.	0.5	37
441	Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian Journal of Ophthalmology, 2017, 65, 596.	0.5	20
442	Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration. Türk Oftalmoloji Dergisi, 2020, 50, 275-282.	0.4	6
443	Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration. ISRN Ophthalmology, 2011, 2011, 1-4.	1.7	2
445	Intraocular Pressure Elevation Following Intravitreal Injection with Antivascular Endothelial Growth Factor. Journal of Current Glaucoma Practice, 2008, , 8-11.	0.1	0
448	Tratamiento de la neovascularización coroidea en el miope magno con inyección intravítrea de antiangiogénicos. , 2010, , 95-100.		0
449	Management of Ruptured Retinal Arterial Macroaneurysm with Intravitreal Bevacizumab. Ophthalmic Surgery, Lasers and Imaging, 2010, 41 Online, e1-5.	0.5	17
450	Trabeculectomy with or without Intraoperative Sub-conjunctival Injection of Bevacizumab in Treating Refractory Glaucoma. Journal of Clinical & Experimental Ophthalmology, 2011, 02, .	0.1	4
451	Combination Therapy with Ocular Photodynamic Therapy for Age-Related Macular Degeneration. , 2011, , 99-118.		0
452	Kombinationstherapien zur Behandlung der AMD. , 2011, , 253-268.		0
454	Bevacizumab and Cataract Surgery in AMD. Highlights of Ophthalmology, 2012, 40, 20-24.	0.0	0
455	Intravitreal bevacizumab injection for management of macular edema in branch retinal vein occlusion. Egyptian Retina Journal, 2013, 1, 45.	0.2	0
456	The Frequency of the Nonresponsiveness to Intravitreal Injection of the Anti-Vascular Endothelial Growth Factor Agent in Neovascular Age Related Macular Degeneration. International Journal of Ophthalmic Pathology, 2013, 02, .	0.1	1
457	Neovascular Age-Related Macular Degeneration: Rationale for Current Treatment Guidelines. Essentials in Ophthalmology, 2013, , 107-125.	0.0	0
458	The Effect of Intravitreal Avastin on Systemic Blood Pressure in Controlled Hypertensive Patients. Journal of Islamic Academy of Sciences, 2013, 21, 77-80.	0.0	2
459	Preoperative intravitreal bevacizumab and silicone oil tamponade for vitrectomy in diabetic retinopathy. World Journal of Ophthalmology, 2014, 4, 75.	0.1	0
460	Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study. Digital Journal of Ophthalmology: DJO, 2016, 22, 46-53.	0.2	6

#	ARTICLE	IF	CITATIONS
461	Efficacy of Anti-VEGF and Subtenon Injection of Triamcinolone Acetonide for Choroidal Neovascularization Associated with Multifocal Choroiditis. <i>Open Journal of Ophthalmology</i> , 2017, 07, 117-123.	0.1	0
462	Intravitreal Ranibizumab/ Lucentis (IVTL) injections in Glaucoma patients-Intraocular Pressure (IOP) elevation and the use of Anterior Chamber Paracentesis (ACP). , 2017, 1, 033-041.		0
463	The non-Responsiveness to Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Neovascularage-Related Macular Degeneration. <i>Advances in Ophthalmology & Visual System</i> , 2017, 6, .	0.2	0
464	Formulations of Extemporaneous Intraocular Injections. , 2020, , 69-89.		0
466	Anti-VEGF Treatment for Age-Related Macular Degeneration. , 2007, , 53-66.		0
467	Intravitreal bevacizumab: an analysis of the evidence. <i>Clinical Ophthalmology</i> , 2007, 1, 273-84.	0.9	8
468	Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin. <i>Molecular Vision</i> , 2009, 15, 1897-905.	1.1	10
470	Delayed corneal epithelial healing after intravitreal bevacizumab: a clinical and experimental study. <i>Journal of Ophthalmic and Vision Research</i> , 2011, 6, 18-25.	0.7	8
471	Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration. <i>Journal of Ophthalmic and Vision Research</i> , 2008, 3, 95-101.	0.7	6
472	Spontaneous or secondary to intravitreal injections of anti-angiogenic agents retinal pigment epithelial tears in age-related macular degeneration. <i>International Journal of Ophthalmology</i> , 2014, 7, 681-5.	0.5	4
473	Anti-vascular endothelial growth factor indications in ocular disease. <i>Romanian Journal of Ophthalmology</i> , 2015, 59, 235-242.	0.4	19
474	Modulated anti-VEGF therapy under the influence of lipid metabolizing proteins in Age related macular degeneration: a pilot study. <i>Scientific Reports</i> , 2022, 12, 714.	1.6	3
475	Risk factors for emerging intraocular inflammation after intravitreal brolocizumab injection for age-related macular degeneration. <i>PLoS ONE</i> , 2021, 16, e0259879.	1.1	25
476	Overcoming Vascular Barriers to Improve the Theranostic Outcomes of Nanomedicines. <i>Advanced Science</i> , 2022, 9, e2103148.	5.6	6
478	Review of Intraocular Inflammation After Antivasular Endothelial Growth Factor Agents. <i>International Ophthalmology Clinics</i> , 2022, 62, 35-47.	0.3	1
480	Considerations When Offering Minimally Proven Investigational Treatments. <i>Ophthalmology</i> , 2023, 130, 351-353.	2.5	1
481	Controversies and Disparities in the Management of Age-Related Macular Degeneration. <i>Seminars in Ophthalmology</i> , 0, , 1-9.	0.8	0
482	Effects on the Contralateral Eye After Intravitreal Bevacizumab and Ranibizumab Injections: A Case Report. <i>Annals of the Academy of Medicine, Singapore</i> , 2008, 37, 591-593.	0.2	43

#	ARTICLE	IF	CITATIONS
483	Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the Tj ETQq0 0 0 rgBT, Overlock 10 Tf 50	0.9	0